Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial

Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 offering more than 50% upside.

On June 24, Verastem Inc. (NASDAQ:VSTM) revealed encouraging initial findings from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375. It is an experimental oral KRAS G12D inhibitor for patients with advanced KRAS G12D-mutated tumors. The results showed encouraging clinical activity and a satisfactory tolerance and safety profile within several dosage levels and tumor types. These included metastatic colorectal cancer, advanced non-small cell lung cancer, and metastatic pancreatic ductal adenocarcinoma.

Copyright: dolgachov / 123RF Stock Photo

According to Verastem Oncology’s President of Development, Michael Kauffman, VS-7375 showed anti-tumor effectiveness across a range of dosages and malignancies. Data also indicated positive outcomes from combination strategies and a favorable safety profile after the first treatment cycle. It also demonstrated concordance when used alongside anti-EGFR therapy and conventional chemotherapy, encouraging its development across colorectal, pancreatic and lung malignancies.

The company plans to enroll patients in three Phase 2 registration-directed trials as a follow-up to the TARGET-D 101 study, and it anticipates sharing further VS-7375 results at the end of this year.

Verastem Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company involved in developing and commercializing drugs for the treatment of cancer. Its product candidates are Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is involved in clinical studies of RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.

While we acknowledge the risk and potential of VSTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VSTM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1